Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Ingelheim GmbH

http://www.boehringer-ingelheim.com/

Latest From Boehringer Ingelheim GmbH

Interchangeable Biosimilars: Insulin Likely First But Humira May Be More Important Precedent

US FDA’s first decision on biosimilars interchangeability might have less meaning for two insulin products, but payer and prescriber responses to interchangeable biosimilars for adalimumab, which are further out on the horizon, may be more instructive regarding the importance of interchangeability status.

Biosimilars Reimbursement

EU Decision Time On Broader Indication For AbbVie’s Skyrizi

The European Medicines Agency is meeting this week to consider applications to broaden the use of approved drugs to include new indications in the EU. 

Drug Review Regulation

Novartis Not Nervous About SGLT2 Threat To Entresto

The company's pharma chief Marie-France Tschudin does not expect Entresto's "unique position" in heart failure to be threatened by SGLT2 inhibitors such as Jardiance and Farxiga, saying those drugs are add-ons that will be used predominantly in diabetes patients.

Cardiovascular Strategy

When Breakthrough Falls Short: US FDA Complete Response Letters Rising Among BTD Applications For Approval

More than half of the complete response letters issued for applications holding breakthrough status have been issued since 2020, reflecting difficult – and often rancorous – efficacy debates.

Drug Review Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • AMAL Therapeutics SA
    • ICD Therapeutics
    • NBE Therapeutics AG
    • SSP Co., Ltd.
    • Vira Therapeutics GmbH (Vira T)
UsernamePublicRestriction

Register